Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

As Amgen waits for an FDA decision on a second ... MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which can lead to muscle weakness, breathing ...

The Jonathan Jaques Children's Cancer Institute at Miller Children's & Women's Hospital was involved in a pivotal Children's Oncology Group study that has reshaped the standard of care for children ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

RBC Capital Markets Global Healthcare Conference May 21, 2025 9:00 AM ETCompany ParticipantsJustin Claeys - VP, IRKave Niksefat ...

Amgen has reported positive phase 3 results ... for additional indications on Soliris' label like generalised myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD).

LONDON, GREATER LONDON, UNITED KINGDOM, May 29, 2025 /EINPresswire.com/ -- What Does The C5 Complement Inhibitors Market Landscape Look Like? The market for C5 complement inhibitors, critical ...

Arrowhead Pharmaceuticals, Inc.'s deal with Sarepta expands its pipeline, but limited plozasiran market and competition ...

J&J ’s JNJ stock has declined 6.4% in the past three months. J&J faces several challenges, including slowing sales in the ...

In this final part of a recent interview with Jonathan Strober, MD, UCSF Benioff Children's Hospital and phase 2/3 ...

The FDA has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis in patients aged 12 years and older who are AChR or anti-muscle-specific tyrosine kinase antibody ...